Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.

Por Fosså, S. D., Sternberg, C., Scher, H. I., Theodore, C. H., Mead, B., Dearnaley, D., Roberts, J. T., Skovlund, E.
Publicado em 1996

Androgen dynamics and serum PSA in patients treated with abiraterone acetate

Por Ryan, C J, Peng, W, Kheoh, T, Welkowsky, E, Haqq, C M, Chandler, D W, Scher, H I, Molina, A
Publicado em 2014

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Por Goodman, O B, Flaig, T W, Molina, A, Mulders, P F A, Fizazi, K, Suttmann, H, Li, J, Kheoh, T, de Bono, J S, Scher, H I
Publicado em 2014

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Por Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., Beer, T. M.
Publicado em 2013

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Por Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I., Carducci, M. A.
Publicado em 2012

Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: Isolation, quantification, and characterization of immune responses by using totally...

Por Wang, Z.-G., Williams, L. J., Zhang, X.-F., Zatorski, A., Kudryashov, V., Ragupathi, G., Spassova, M., Bornmann, W., Slovin, S. F., Scher, H. I., Livingston, P. O., Lloyd, K. O., Danishefsky, S. J.
Publicado em 2000

Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

Por Slovin, S. F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W. G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K. O., Livingston, P. O., Danishefsky, S. J., Scher, H. I.
Publicado em 1999

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can...

Por Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C
Publicado em 2013

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Por Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Publicado no Ann Oncol (2016)

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Por Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., Davis, I.D., de Bono, J.S., Evans, C.P., Fizazi, K., Joshua, A.M., Kim, C.-S., Kimura, G., Mainwaring, P., Mansbach, H., Miller, K., Noonberg, S.B., Perabo, F., Phung, D., Saad, F., Scher, H.I., Taplin, M.-E., Venner, P.M., Tombal, B.
Publicado no N Engl J Med (2014)

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Por Pritchard, C.C., Mateo, J., Walsh, M.F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., Elemento, O., Rubin, M.A., Robinson, D., Lonigro, R., Hussain, M., Chinnaiyan, A., Vinson, J., Filipenko, J., Garraway, L., Taplin, M-E., AlDubayan, S., Han, G.C., Beightol, M., Morrissey, C., Nghiem, B., Cheng, H.H., Montgomery, B., Walsh, T., Casadei, S., Berger, M., Zhang, L., Zehir, A., Vijai, J., Scher, H.I., Sawyers, C., Schultz, N., Kantoff, P.W., Solit, D., Robson, M., Van Allen, E.M., Offit, K., de Bono, J., Nelson, P.S.
Publicado no N Engl J Med (2016)

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Por Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A., Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F., Tombal, B.
Publicado no Ann Oncol (2015)